NCT05046613Recruiting
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 780 (estimated)
- First submitted
- 8 Sept 2021
- Start date
- 23 Sept 2021
- Primary completion date
- 4 Nov 2029
- Lead sponsor
- Pfizer
- Diseases
- Migraine
- NCT number
- NCT05046613
What you commit to
- Study type: Observational
- Planned participants: 780
- From 23 Sept 2021 to the primary completion date, 4 Nov 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Women exposed to other calcitonin gene-related peptide (CGRP)antagonists (e.g., ubrogepant), CGRP monoclonal antibodies, or ditans (e.g., lasmiditan) at any time during pregnancy or just prior to pregnancy
Who the study is looking for
- Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days prior to conception)
- Pregnant women with migraine unexposed to rimegepant: a diagnosis of migraine and no exposure to Rimegepant before or during pregnancy
Age in the registry: 0 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Evidera, a PPD business unit Coordinator of this site? Confirm its status | Wilmington | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.